|Articles|September 20, 2018

OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research

Sorrento Therapeutics, Inc., a clinical stage, antibody-centric, biopharmaceutical company, has signed a new agreement with OmniComm Systems, Inc., a global provider of clinical data management technology, in which they will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Sorrento research sites.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

ByAndy Studna, Senior Editor

August 12th 2026

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ByOtis Johnson, PhD, MPA,Andy Studna, Senior Editor,Joseph Kim,Lauren Briggs

August 12th 2026

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

ByAndy Studna, Senior Editor

August 12th 2026

© photon_photo - © photon_photo - stock.adobe.com

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

ByMario Alejandro Castellanos Urdaibay, MD, MSc

August 11th 2026

Breaking the Efficacy Ceiling in IBD and Beyond

ByMichael Christel,Kori Wallace, MD, PhD

August 11th 2026

OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research

Related Content

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Breaking the Efficacy Ceiling in IBD and Beyond

Trending on Applied Clinical Trials Online

Breaking the Efficacy Ceiling in IBD and Beyond

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment